2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Cyngn reported second-quarter 2026 results with revenue of $144,459, up from $33,726 a year earlier, while its net loss widened to $6.4 million from $5.4 million as total costs rose 25%. The company said commercial execution was delayed relative to its expectations, and it has reduced management layers and changed sales leadership. Cash and short-term investments totaled $39.7 million at June 30, 2026, and the company reported no debt.
Q2 2026 revenue was $144,459, compared with $33,726 in Q2 2025.
Q2 2026 net loss was $(6.4) million, or $(0.45) per share, on about 14.1 million weighted-average shares, versus $(5.4) million, or $(2.70) per share, on about 2.0 million shares in Q2 2025.
Total costs and expenses rose $1.4 million, or 25%, to $6.9 million, mainly from a $1.2 million increase in research and development.
Cash and short-term investments were $39.7 million at June 30, 2026, versus $34.7 million at December 31, 2025.
BioStem Technologies reported second quarter 2026 results on August 12, 2026, with net revenue of $7.9 million, up 29% from $6.1 million in the first quarter but down from $11.0 million in the second quarter of 2025. The company raised its full-year 2026 revenue guidance to $26 million to $29 million, but posted a GAAP net loss of $9.0 million, or $0.52 per share, and cash and cash equivalents fell to $7.0 million at June 30, 2026.
Net revenue of $7.9 million, up 29% from $6.1 million in Q1 2026 and down from $11.0 million in Q2 2025
GAAP net loss of $9.0 million, or $0.52 per share, versus net income of $10,613 in Q2 2025; gross margin 61% versus 94% a year earlier
Full-year 2026 revenue guidance raised to $26 million to $29 million from $25 million to $29 million
Cash and cash equivalents of $7.0 million at June 30, 2026, compared with $13.7 million at the end of Q1 2026
GMR Solutions reported second-quarter 2026 net revenue of $1,490.3 million, up 3.3%, but swung to a net loss of $28.3 million from net income of $80.8 million a year earlier. Adjusted EBITDA fell 11.8% to $284.5 million, and the company reaffirmed its full-year 2026 guidance, which means shareholders should weigh the revenue growth against lower profit.
Q2 2026 net revenue was $1,490.3 million, up 3.3% from $1,442.0 million in Q2 2025.
Q2 2026 net loss was $28.3 million, compared with net income of $80.8 million in Q2 2025; adjusted EBITDA was $284.5 million, down 11.8%.
Full-year 2026 guidance was reaffirmed: net revenue of $5,890 million to $6,180 million and adjusted EBITDA of $1,135 million to $1,195 million.
The CFO said the prior-year period benefited from a $74.3 million year-over-year difference in revenue estimate changes tied to No Surprises Act collections.
Santander Holdings USA reported second-quarter 2026 net income of $585 million, up 41.2% from the prior quarter and 17.5% from a year earlier, in a fixed income investor presentation furnished under Items 2.02 and 7.01. The filing also said the Federal Reserve approved the acquisition of Webster Financial Corporation on August 4, 2026, and that the deal is now expected to close on August 20, 2026.
Q2 2026 net income of $585 million, up 41.2% from Q1 2026 and up 17.5% from Q2 2025
Net interest income of $1.5 billion, up 1.7% from Q1 2026 and up 2.7% from Q2 2025
Federal Reserve approved the Webster Financial acquisition on August 4, 2026; closing expected August 20, 2026
CET1 ratio of 13.7% at June 30, 2026, up from 13.0% in Q1 2026
Pershing Square Inc. reported second quarter 2026 results on August 12, 2026, with the full press release and earnings presentation attached as Exhibit 99.1. The filing text provided does not include the quarter's revenue, profit or guidance figures, so the direction of results cannot be confirmed from it. The company also noted a $0.122 per share dividend paid July 21, 2026, and a shareholder call on August 13, 2026.
Q2 2026 results are in Exhibit 99.1; the revenue and profit figures are not in the text provided.
Dividend of $0.122 per common share paid July 21, 2026, to holders of record as of July 13, 2026.
Investor call on August 13, 2026 at 9:00 a.m. ET, followed by an X Spaces Q&A at 10:00 a.m. ET.
Investor withdrawals of $354 million (AUM) and $273 million (fee-paying AUM) from PSLP and PSINTL to take part in the PSUS IPO; no corporate income tax was incurred in Q2 2026, but the company expects to pay it in future periods.
M-tron Industries (Mtron) reported second-quarter 2026 results, with revenue up 13.8% to $15.1 million and net income up 19.9% to $1.9 million. Diluted earnings per share fell to $0.43 from $0.53, which the company attributes to more weighted shares outstanding after a rights offering completed in April 2026. Shareholders get higher sales and profit in dollar terms, but per-share earnings were diluted, and management will discuss the results on a call on August 13, 2026.
Revenue of $15.1 million for the quarter, up 13.8% from $13.3 million a year earlier
Net income of $1.9 million, up 19.9%; diluted EPS of $0.43 versus $0.53, down 18.9%
Diluted EPS decline attributed to higher weighted shares outstanding from the rights offering completed in April 2026
Backlog of $84.0 million as of June 30, 2026, up 37.2% from $61.2 million a year earlier; conference call August 13, 2026 at 10:30 a.m. ET
Dolphin Entertainment reported second-quarter 2026 revenue of $14.4 million, up 2.5% from a year earlier, and first-half revenue of $27.2 million, up 3.8%. Net loss rose to $1.6 million from $1.4 million, and adjusted EBITDA fell to about $243,000 from about $628,000, as retention bonuses and litigation-related legal costs weighed on results.
Q2 2026 revenue was $14.4 million versus $14.1 million in Q2 2025; H1 2026 revenue was $27.2 million versus $26.3 million.
Q2 2026 operating loss was $1.0 million versus $0.1 million in Q2 2025; net loss was $1.6 million, or $(0.13) per share, unchanged from the prior-year loss per share.
Retention bonuses of $360,000 and litigation-related costs of about $0.4 million affected the quarter; the company says the bonuses are not expected to recur.
Cash and cash equivalents were $7.7 million at June 30, 2026, down from $8.8 million at December 31, 2025.
Tecogen reported second-quarter 2026 revenue of $5.75 million, down 21.2% from $7.29 million a year earlier, and a net loss of $2.15 million, or $(0.07) per share, versus a net loss of $1.46 million, or $(0.06) per share, in the same period of 2025. Management attributed the wider loss to lower Products segment gross profit and higher operating expenses, and said it expects third-quarter product revenue to exceed the first two quarters of 2026.
Q2 2026 Products revenue fell 64.0% to $1.13 million, while Services revenue rose 10.3% to $4.38 million.
Six-month net loss was $4.27 million, compared with $2.12 million a year earlier; cash and cash equivalents were $6.78 million at June 30, 2026.
Non-data center backlog was approximately $8 million, with $2 million or more in additional orders expected over the next few months, according to the CEO.
The company will hold an earnings conference call on August 13, 2026, at 9:30 am ET, with slides furnished as Exhibit 99.2.
CuriosityStream reported second-quarter 2026 revenue of $23.2 million, up from $19.0 million a year earlier, with net income of $8.9 million compared with $0.8 million. The company raised its full-year 2026 revenue and adjusted EBITDA guidance and declared a $0.085 quarterly dividend, which matters to shareholders because it reflects higher reported profit and a higher outlook.
Q2 2026 revenue was $23.2 million, up 22% from $19.0 million in Q2 2025; licensing revenue was $14.1 million, up 48%.
Q2 2026 net income was $8.9 million, or $0.15 per diluted share, versus $0.8 million in Q2 2025; adjusted EBITDA was $11.4 million versus $3.0 million.
Full-year 2026 revenue guidance is $77 million to $82 million, and full-year adjusted EBITDA guidance is $18 million to $22 million.
Quarterly dividend of $0.085 per share is payable September 18, 2026, to holders of record on September 4, 2026.
Mexco Energy reported net income of $501,065 for the quarter ended June 30, 2026, up 107% from a year earlier, and operating revenues rose 13% to $1,983,169. Revenue growth came mainly from a 52% higher average oil price, partly offset by a 15% drop in oil production, which matters to shareholders because the company's earnings depend on both prices and output.
Net income was $501,065, or $0.24 per diluted share, versus $241,951, or $0.12 per diluted share, in the prior-year quarter.
Operating revenues were $1,983,169, up 13% from $1,756,940, driven by a 52% increase in average oil price.
Oil production fell 15% and natural gas production fell 9%, while the average natural gas price fell 49%.
The company spent approximately $2.1 million on oil and gas royalty property acquisitions, funded from existing cash, and expects drilling and completion costs of approximately $1.8 million for the fiscal year ending March 31, 2027.
Park Dental Partners reported second-quarter 2026 revenue up 5.1% to $66.2 million, but net income fell 47.5% to $1.3 million, or $0.22 per diluted share, from $2.6 million, or $1.45, a year earlier. The company also issued full-year 2026 outlook of $256.0 million to $260.0 million in revenue and $21.0 million to $23.0 million in Adjusted EBITDA, excluding the pending Village Family DSO acquisition.
Q2 2026 revenue rose 5.1% to $66.2 million; Adjusted EBITDA fell 1.7% to $7.4 million.
Q2 2026 diluted EPS was $0.22 versus $1.45 in Q2 2025; adjusted diluted EPS was $0.66 versus $1.88.
2026 outlook: revenue $256.0 million to $260.0 million; Adjusted EBITDA $21.0 million to $23.0 million, compared with 2025 actual revenue of $244.5 million and Adjusted EBITDA of $22.0 million.
Entered a definitive agreement to acquire Village Family DSO, expected to close later this year; the outlook does not include it.
EquipmentShare reported second-quarter 2026 revenue of $1,449 million, up 26% from a year earlier, with net income of $19 million compared with $16 million. Diluted earnings per share were $0.06 in both periods, and the company reiterated its 2026 outlook, which projects total revenue of $5,254 million to $5,682 million and Adjusted Core EBITDA of $1,946 million to $2,058 million.
Q2 2026 total revenue $1,449 million, up 26% from $1,147 million; Rental Segment revenue $908 million, up 39%
Net income $19 million vs. $16 million a year earlier; GAAP diluted EPS $0.06 in both periods
Adjusted Core EBITDA $531 million, up 34% from $395 million; includes $24 million of IPO Founders Awards stock compensation excluded from Adjusted Net Income
2026 outlook: total revenue $5,254 million to $5,682 million; Adjusted Core EBITDA $1,946 million to $2,058 million
Kimball Electronics reported fourth-quarter fiscal 2026 net sales of $371.6 million, down 2% from a year earlier but up 5% from the prior quarter. Adjusted diluted EPS was a loss of $0.01, compared with $0.34 a year earlier, while GAAP diluted EPS rose to $0.35 from $0.26, helped by a $15.0 million gain on disposal. The company guided fiscal 2027 net sales of $1,535 million to $1,560 million, which includes about $60 million from the Helvoet acquisition.
Q4 net sales $371.6 million vs. $380.5 million a year earlier; adjusted operating income $18.1 million vs. $19.6 million
Q4 GAAP diluted EPS $0.35 vs. $0.26; adjusted diluted EPS $(0.01) vs. $0.34
Fiscal 2026 net sales $1,431.4 million, down 4% from $1,486.7 million; adjusted diluted EPS $1.09 vs. $1.12
Fiscal 2027 guidance: net sales $1,535 million to $1,560 million (7% to 9% growth) and adjusted operating income of 4.4% to 4.7% of net sales
Crown Crafts reported first-quarter fiscal 2027 net sales of $16.8 million and net income of $2.1 million, compared with a net loss of $1.1 million a year earlier. Gross profit was helped by $3.7 million in tariff refunds, and the Board declared a $0.03 per share quarterly dividend. Stockholders also approved an amended 2021 Incentive Plan that raises the share reserve to 2,450,000 shares.
Net sales rose to $16.8 million from $15.5 million in the prior-year quarter ended June 29, 2025.
Net income was $2.1 million, or $0.19 per share, versus a net loss of $1.1 million, or $0.10 per share, a year earlier.
Gross profit included $3.7 million in tariff refunds; excluding refunds, gross margin was 25.6%, up 290 basis points year over year.
The $0.03 per share dividend is payable October 2, 2026 to holders of record on September 11, 2026.
Stem, Inc. reported results for the quarter ended June 30, 2026, with revenue down 12% year over year to $33.7 million and a net loss of $14.4 million, compared with net income of $202.5 million a year earlier that included a one-time gain on debt extinguishment. Adjusted EBITDA rose 63% to $6.2 million, and the company reaffirmed its full-year 2026 guidance across all metrics.
Revenue was $33.7 million, down from $38.4 million in Q2 2025, due to significantly reduced battery hardware resales and lower managed services revenue.
Software, services, and edge hardware revenue rose 1% to $33.4 million, with PowerTrack software revenue up 11% year over year.
Net loss was $14.4 million versus net income of $202.5 million in Q2 2025; the prior-year quarter included a one-time gain on extinguishment of debt.
Full-year 2026 guidance was reaffirmed, including revenue of $140 million to $190 million and adjusted EBITDA of $10 million to $15 million.
Solidion Technology reported second-quarter 2026 results in a press release furnished under Item 2.02. Net sales were $124,914, up from $4,000 a year earlier, mainly from government grant revenue, while the net loss widened to $2.9 million from a restated $2.1 million. The company said that after a $35 million private placement, substantial doubt about its ability to continue as a going concern has been alleviated.
Net sales of $124,914 for the quarter ended June 30, 2026, versus $4,000 a year earlier, mainly from government grant revenue.
Net loss of $2.9 million, or $0.35 per basic share, versus a restated $2,113,859 loss a year earlier; includes a $917,780 loss from change in fair value of derivative liabilities.
Cash and cash equivalents of $27.7 million at June 30, 2026, compared with $0.2 million at December 31, 2025.
A $35 million private placement closed June 9, 2026; the company said the going concern doubt was alleviated after it closed.
StubHub reported second-quarter 2026 revenue of $573.1 million, up 33% from a year earlier, and net income of $14.6 million compared with a net loss of $53.8 million in the prior-year quarter. The company raised its full-year 2026 gross merchandise sales (GMS) outlook to $10.1 billion to $10.3 billion and reiterated its adjusted EBITDA outlook of $400 million to $420 million, which signals improved operating results for shareholders.
Revenue of $573.1 million, up 33% from $430.3 million; GMS of $3.1 billion, up 34%
Net income of $14.6 million versus a net loss of $53.8 million a year earlier; adjusted EBITDA of $105.7 million, up 94%
Full-year 2026 GMS outlook raised to $10.1 billion to $10.3 billion; adjusted EBITDA outlook of $400 million to $420 million reiterated
Free cash flow of $309.7 million versus $9.7 million; year-to-date debt reduction of $200.0 million
FGI Industries reported second-quarter 2026 revenue of $31.9 million, up 2.9% from a year earlier, with gross margin rising to 33.4% from 28.1%. The company posted net income attributable to shareholders of $1.3 million, or $0.65 per diluted share, compared with a loss of $1.2 million, or $0.64 per diluted share, a year earlier. The company reaffirmed its fiscal 2026 guidance, which includes total net revenue of $134-141 million.
Q2 2026 revenue was $31.9 million, up 2.9% year over year; gross profit was $10.7 million, up 22.5%.
Operating income was $1.4 million, compared with an operating loss of $0.8 million in Q2 2025.
Diluted EPS was $0.65 versus a loss of $0.64 a year earlier; cash was $4.4 million and total liquidity was $7.9 million at June 30, 2026.
Fiscal 2026 guidance was reaffirmed, with total net revenue of $134-141 million and adjusted operating income of $0.7-2.5 million.
Fossil Group reported fiscal second-quarter 2026 net sales of $209.7 million, down 4.9% from $220.4 million a year earlier, and a net loss of $10.6 million, or $0.18 per diluted share, versus a $2.3 million loss, or $0.04 per share, in the prior-year quarter. The company also raised its full-year 2026 outlook, now calling for worldwide net sales to decline 3% to 5% and an adjusted operating margin of 4% to 6%, with positive free cash flow.
Gross margin rose 490 basis points to 62.4%, but operating expenses rose 7.9% to $127.6 million.
Operating income was $3.2 million, compared with $8.5 million in the second quarter of 2025; constant currency adjusted operating income was $8.6 million, compared with $4.3 million in the prior-year quarter.
Cash and cash equivalents were $79.0 million at July 4, 2026, and total debt was $203.0 million.
Full-year guidance: worldwide net sales down 3% to 5%, with a return to growth expected in the fourth quarter.
Kailera Therapeutics reported a second-quarter 2026 net loss of $111.3 million, up from $28.9 million a year earlier, as research and development expenses rose to $101.1 million from $19.5 million. The company had $1,171.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects to fund operations into mid-2028. For shareholders, the filing shows a much larger loss driven by expanded clinical development, and the statement of operations reports no revenue.
Q2 2026 net loss was $111.3 million, compared with $28.9 million in Q2 2025.
R&D expenses were $101.1 million versus $19.5 million; G&A expenses were $20.3 million versus $11.1 million.
Cash, cash equivalents and marketable securities totaled $1,171.8 million as of June 30, 2026, with runway into mid-2028.
Ribupatide oral has an active U.S. FDA IND; global Phase 3 obesity trial initiation is planned for the first half of 2027.
Marchex reported second-quarter 2026 revenue of $11.0 million, down from $11.7 million a year earlier, and a net loss of $0.4 million, or $(0.01) per diluted share, compared with net income of $0.1 million a year earlier. Adjusted EBITDA rose to $0.7 million from $0.6 million, but the Archenia acquisition, which closed July 1, 2026, is not included in these reported results, and the company gave a third-quarter pro forma combined revenue outlook of $16.0 million to $16.5 million.
Q2 2026 revenue was $11.0 million, compared with $11.7 million in Q2 2025.
Q2 2026 net loss was $0.4 million, or $(0.01) per diluted share, versus net income of $0.1 million, or $0.00 per share, a year earlier.
Adjusted EBITDA was $0.7 million, including $1.0 million of reorganization and acquisition-related costs; adjusted non-GAAP income per share was $0.00 versus $0.02.
Third-quarter 2026 pro forma combined outlook: revenue of $16.0 million to $16.5 million and adjusted EBITDA, net of reorganization and acquisition costs, of $2.3 million to $2.5 million.
Infleqtion reported second-quarter 2026 revenue of $12.6 million, up 116% year over year, and raised its full-year 2026 revenue outlook to approximately $43 million. The net loss widened to $25.5 million from $8.8 million a year earlier, and the company ended the quarter with $582 million in cash, cash equivalents, restricted cash and available-for-sale securities and no debt.
Q2 2026 revenue was $12.6 million, up 116% year over year; the company said growth was 100% organic and entirely from quantum
GAAP operating loss was $30.6 million, compared with $10.1 million in Q2 2025; non-GAAP operating loss was $17.0 million, compared with $7.3 million
2026 revenue outlook was raised to approximately $43 million, and the 30 logical qubit target was reiterated
Results included a $27.4 million temporary working-capital benefit from payroll taxes not yet remitted; the company expects to remit it in Q3
BitGo reported second-quarter 2026 revenue of $4.3 billion, up 79.6% from a year earlier, but swung to a net loss of $19.0 million from a net income of $38.3 million in Q2 2025. The same day, CFO Edward Reginelli said he will resign effective September 15, 2026, and the company has started a search for his successor.
Total revenue of $4.3 billion in Q2 2026, up 79.6% year-over-year and 14.7% sequentially, driven mainly by Digital Asset Sales
Net loss of $19.0 million, or $(0.16) per share, compared with net income of $38.3 million in Q2 2025, mainly due to an $18.8 million unrealized loss on digital assets
Adjusted EBITDA loss of $4.2 million; the company authorized a share repurchase program of up to $50 million
CFO Edward Reginelli to resign effective September 15, 2026, then serve in an advisory role during the transition
Resideo reported second quarter 2026 revenue of $1.98 billion, up 2% year over year, with net income of $97 million versus a net loss of $825 million a year earlier and diluted EPS of $0.51. The company also completed the spin-off of ADI Global Distribution on August 3, 2026, and named Shane Harrison Senior Vice President and Chief Financial Officer effective September 1, 2026.
Q2 2026 adjusted EPS was $0.83, up 26% from a year earlier, and adjusted EBITDA was $249 million, up 19%.
GAAP income from operations fell 26% to $131 million, with $31 million of business separation costs in the quarter.
Resideo initiated standalone outlook: third quarter 2026 revenue of $705 million to $730 million and full-year 2026 revenue of $2.90 billion to $2.95 billion.
EnerSys reported first quarter fiscal 2027 net sales of $935.6 million, up 4.8% from a year earlier, and GAAP diluted EPS of $3.09 versus $1.46. Adjusted diluted EPS of $3.66 came in above the company's May 20 guidance range of $2.80 to $2.90. The Board also raised the quarterly dividend 10% to $0.2875 per share, and the company guided second quarter net sales to $955 million to $995 million.
Net sales of $935.6 million, up 4.8% from $893.0 million; GAAP diluted EPS of $3.09 versus $1.46.
Adjusted diluted EPS of $3.66, above the $2.80 to $2.90 guidance range; results include $30.9 million of tariff refunds.
Second quarter fiscal 2027 outlook: net sales of $955 million to $995 million and adjusted diluted EPS of $3.15 to $3.25.
Quarterly dividend raised 10% to $0.2875 per share, payable October 2, 2026, to holders of record as of September 18, 2026.
Armata Pharmaceuticals reported second-quarter 2026 net income of $74.1 million, driven by a $91.0 million non-cash gain from the change in fair value of its Convertible Loan. Operating loss widened to $10.3 million from $6.8 million a year earlier, and the company's cash and equivalents were $24.0 million at June 30, 2026, so the profit does not reflect improved operations.
Q2 2026 grant and award revenue was $2.5 million, up from $2.2 million in Q2 2025.
Q2 2026 research and development expenses rose to $7.6 million and general and administrative expenses to $5.2 million, mainly from higher non-cash stock-based compensation.
Q2 2026 diluted loss per share was $0.27, compared with $0.45 in Q2 2025; basic earnings per share were $2.02.
Six-month net loss widened to $41.2 million from $22.8 million; cash and equivalents were $24.0 million at June 30, 2026.
Gaxos.ai reported record second-quarter 2026 revenue of $2.46 million, up 35.8% from the first quarter and up 1,337% from the second quarter of 2025, while advertising and marketing expense rose about 13.5%. GAAP net income was $241,056, or $0.02 per share, mainly from a gain on the sale of its gaming assets to Game Foundry AI, so the profit may not repeat in future quarters. The filing gives no financial guidance for future periods.
Q2 2026 revenue was $2.46 million, up 35.8% from $1.81 million in Q1 2026 and up 1,337% from $0.17 million in Q2 2025.
GAAP net income was $241,056, or $0.02 per basic and diluted share, primarily reflecting a gain from the gaming asset sale.
Advertising and marketing expense was $3,141,273 in Q2, compared with $2,766,824 in Q1 2026.
Cash and short-term investments were about $11.44 million at June 30, 2026, versus $11.71 million at March 31, 2026.
Atea Pharmaceuticals reported a narrower second-quarter net loss of $32.9 million, down from $37.2 million a year earlier, as lower research and development and general and administrative spending more than offset lower interest income. Cash and investments fell from $301.8 million at December 31, 2025 to $219.5 million at June 30, 2026. The release also restates the July C-BEYOND Phase 3 results and gives timing for C-FORWARD topline data and a planned new drug application, which shape the company's path to a possible US launch of BEM/RZR.
Net loss of $32.9 million, or $0.41 per share, for the three months ended June 30, 2026, versus $37.2 million, or $0.44 per share, a year earlier.
Research and development expenses fell to $28.2 million from $32.3 million; general and administrative expenses fell to $7.0 million from $9.1 million.
Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025.
C-FORWARD Phase 3 topline results are expected in early first quarter 2027; a new drug application submission is anticipated in the second quarter of 2027.
MaxCyte reported second-quarter 2026 revenue of $7.3 million, down 15% from a year earlier, while its net loss narrowed to $8.9 million from $12.4 million. The company reiterated full-year 2026 revenue guidance of $30 million to $32 million, so shareholders get a smaller loss alongside a shrinking top line.
Total revenue $7.3 million vs. $8.5 million in Q2 2025, down 15%; core revenue down 21% to $6.5 million
Net loss $8.9 million vs. $12.4 million a year earlier; operating expenses $15.8 million vs. $21.2 million
Full-year 2026 revenue guidance of $30 million to $32 million reiterated; year-end cash expected to be at least $130.5 million
Repurchased about $5.5 million of common stock to date under a $10 million buyback; cash and investments $141.9 million at June 30, 2026
Alto Neuroscience reported a second-quarter 2026 net loss of $27.6 million, up from $17.7 million a year earlier, as research and development spending rose to $22.1 million from $13.1 million. The company said it had about $338 million in pro forma cash after a July 2026 offering, which it expects to fund planned operations through 2030, and it added a Phase 3 monotherapy trial of ALTO-207 to its development plan.
Q2 2026 net loss was $27.6 million, versus $17.7 million in Q2 2025; net loss per share was $0.65 in both periods.
R&D expenses were $22.1 million versus $13.1 million; G&A expenses were $7.0 million versus $5.6 million.
Cash, cash equivalents, and restricted cash were $244.2 million at June 30, 2026, versus $177.0 million at December 31, 2025.
July 2026 registered direct offering raised gross proceeds of about $100.0 million; pro forma cash is about $338 million.
Lulus reported second quarter 2026 results for the period ended June 28, 2026, with net revenue down 17% year over year to $67.8 million. Net loss narrowed to $1.5 million from $3.0 million, and gross margin rose 330 basis points to 48.6%, but the company said revenue trends remain below historical levels. The company reaffirmed its fiscal 2026 outlook, including positive Adjusted EBITDA and capital expenditures of $2.0 million to $2.5 million.
Net revenue fell 17% to $67.8 million, driven by a 17% decrease in Total Orders Placed and higher return rates.
Net loss was $1.5 million, or $(0.52) per share, compared with a net loss of $3.0 million, or $(1.08) per share, a year earlier.
Gross margin increased to 48.6% from 45.3%, and inventory fell 23% to $28.6 million.
Lulus reaffirmed its fiscal 2026 outlook for positive Adjusted EBITDA and net revenue growth trend improvement.
Virgin Galactic reported a second-quarter 2026 net loss of $56 million, down from $67 million a year earlier, helped by an $8.6 million gain on extinguishment of debt. Revenue fell to $0.1 million from $0.4 million, and the company said its first commercial spaceflight has moved to February 2027 from the fourth quarter of 2026 to complete systems installations.
Net loss of $56 million versus $67 million in Q2 2025; revenue of $0.1 million versus $0.4 million
First commercial spaceflight moved to February 2027 from the fourth quarter of 2026
Free cash flow guidance: $(95) million to $(100) million in Q3 2026 and $(80) million to $(90) million in Q4 2026
Cash, cash equivalents and marketable securities of $286 million as of June 30, 2026
Connect Biopharma reported results for the three and six months ended June 30, 2026. Revenue rose to $2.8 million for the quarter, mainly from a regulatory milestone under its Simcere license, but the net loss widened to $17.3 million, or $0.27 per share, from $12.9 million, or $0.23 per share, a year earlier, as research and development expense nearly doubled. The company said its $31.5 million in cash, cash equivalents and short-term investments should fund operations for at least one year from the release date, and it expects topline data from its two Phase 2 Seabreeze STAT studies in September 2026.
Q2 2026 license and collaboration revenue was $2.8 million, versus $48,000 in Q2 2025, primarily from a regulatory-based milestone net of development cost sharing.
Q2 2026 research and development expense was $16.3 million, up from $8.8 million, mainly due to rademikibart development costs for the Seabreeze STAT studies.
Q2 2026 net loss was $17.3 million, or $0.27 per share, compared with $12.9 million, or $0.23 per share, in Q2 2025.
Cash, cash equivalents and short-term investments were $31.5 million as of June 30, 2026, down from $44.3 million at December 31, 2025; topline data from the Phase 2 studies are expected in September 2026.
Allogene Therapeutics reported a second-quarter 2026 net loss of $42.7 million, or $0.13 per share, compared with $50.9 million, or $0.23 per share, a year earlier. The company also reported $423.6 million in cash, cash equivalents and investments as of June 30, 2026, and said that cash should fund operations into 2029. The filing furnishes a press release that also gives an update on its pivotal ALPHA3 trial of cema-cel in large B-cell lymphoma, including an interim MRD clearance result and FDA designations.
Second-quarter 2026 collaboration revenue from a related party was $4.6 million, versus none a year earlier.
Net loss was $42.7 million for the quarter ended June 30, 2026, versus $50.9 million in the same quarter of 2025.
Guidance: 2026 operating expense is expected to be about $165 million, and GAAP operating expenses about $225 million, excluding potential business development activity.
In the interim analysis, 58.3% (7/12) of cema-cel arm patients achieved MRD negativity versus 16.7% (2/12) in the observation arm; the FDA granted RMAT and Fast Track designations in July.
Alpha and Omega Semiconductor (AOS) reported fiscal fourth-quarter revenue of $170.4 million, down 3.5% from a year earlier and up 4.0% from the March quarter, with a GAAP net loss of $13.1 million, or $0.43 per diluted share, compared with a $77.1 million loss a year earlier. It guided fiscal first-quarter revenue to $176 million, plus or minus $10 million. Revenue and non-GAAP profit declined year over year, while the quarter improved from the prior quarter.
Q4 revenue was $170.4 million, versus $176.5 million a year earlier and $163.8 million in the March 2026 quarter.
GAAP net loss was $13.1 million ($0.43 per diluted share), versus a $77.1 million loss ($2.58 per share) a year earlier; non-GAAP net loss was $0.13 per share, versus non-GAAP earnings of $0.02 per share a year earlier.
Fiscal 2026 revenue was $678.9 million, versus $696.2 million in fiscal 2025; GAAP net loss was $42.3 million, versus $97.0 million.
Guidance for the quarter ending September 30, 2026: revenue of $176 million plus or minus $10 million and non-GAAP gross margin of 24.5% plus or minus 1%.
SeaStar Medical reported second quarter 2026 results, with net revenue of about $0.6 million, up from about $0.3 million a year earlier, driven by growth in QUELIMMUNE sales. The net loss widened to about $3.7 million, or $0.91 per share, from about $2.0 million, or $1.77 per share, as research and development and general and administrative expenses rose, and cash fell to $7.0 million at June 30, 2026 from $12.0 million at December 31, 2025.
Net revenue for the quarter was about $0.6 million versus about $0.3 million in the second quarter of 2025; the company added 3 new QUELIMMUNE customers, bringing the total to 20.
Research and development expenses rose to $2.5 million from $1.0 million, and general and administrative expenses rose to about $1.8 million from $1.0 million.
Net loss was about $3.7 million, or $0.91 per share, on about 4.1 million weighted-average shares, compared with about $2.0 million, or $1.77 per share, on about 1.1 million shares a year earlier.
Cash was $7.0 million at June 30, 2026, down from $12.0 million at December 31, 2025.
Atara reported a second-quarter 2026 net loss of $4.8 million, or $(0.32) per share, compared with net income of $2.4 million, or $0.20 per basic share, a year earlier. Revenue fell to $0.6 million from $17.6 million, mainly because deferred revenue was recognized in 2025 after development moved to Pierre Fabre. The company says it expects to fund operations into mid-2027, but cash stood at $9.9 million at June 30, 2026.
Commercialization revenue was $0.6 million for Q2 2026, down from $17.6 million in Q2 2025.
Net loss was $4.8 million, or $(0.32) per share, versus net income of $2.4 million in Q2 2025.
Cash, cash equivalents and short-term investments totaled $9.9 million at June 30, 2026, and are expected to fund planned operations into mid-2027.
Total costs and operating expenses fell to $5.4 million from $14.4 million a year earlier; a Type A meeting with the FDA on tabelecleucel was described as productive, with a regulatory update expected later in the quarter.
Acrivon Therapeutics reported a second-quarter 2026 net loss of $18.0 million, down from $21.0 million a year earlier, as research and development and general and administrative expenses declined. The company said its cash, cash equivalents and investments of $90.0 million are expected to fund operations into the fourth quarter of 2027. The company also reiterated that interim data from the ACR-368 Phase 2b study are expected in the second half of 2026.
Net loss per share was $0.43 for the quarter ended June 30, 2026, versus $0.55 a year earlier.
Research and development expenses were $13.8 million, versus $16.2 million; the company said two ACR-368 milestones achieved in 2025 did not recur in 2026.
General and administrative expenses were $4.8 million, versus $6.5 million, mainly due to lower employee-related expenses, including stock-based compensation.
Cash, cash equivalents and investments totaled $90.0 million as of June 30, 2026.
Kura Oncology reported second quarter 2026 results, its second full quarter of KOMZIFTI sales. Total revenue rose to $20.9 million from $15.3 million a year earlier, but the net loss widened to $68.3 million, or $0.77 per share, from $66.1 million, or $0.75 per share. Cash, cash equivalents and short-term investments fell to $519.0 million at June 30, 2026, from $667.2 million at December 31, 2025, and the company cites $180 million in expected collaboration payments from Kyowa Kirin.
Net product revenue was $9.1 million, compared with none in 2Q 2025; new patient starts were about 115, up 35% from 1Q 2026.
Collaboration revenue fell to $11.8 million from $15.3 million in 2Q 2025.
Net loss was $68.3 million, or $0.77 per share, versus $66.1 million, or $0.75 per share, a year earlier.
Cash and short-term investments were $519.0 million at June 30, 2026, plus $180 million in anticipated Kyowa Kirin collaboration payments.
Coherent reported fourth-quarter fiscal 2026 revenue of $2.05 billion, up 34% from a year earlier, and GAAP diluted earnings of $1.19 per share, compared with a loss of $0.83 per share in the same quarter last year. The company also guided first-quarter fiscal 2027 revenue to $2.2 billion to $2.4 billion and non-GAAP EPS to $1.85 to $2.05.
Q4 fiscal 2026 revenue was $2.05 billion, up 34% year over year and up 13.3% from the prior quarter.
GAAP gross margin was 38.5%, up 277 basis points year over year; non-GAAP gross margin was 40.2%.
Q4 non-GAAP diluted EPS was $1.74, up $0.74 from $1.00 a year earlier.
Q1 fiscal 2027 guidance: revenue of $2.2 billion to $2.4 billion and non-GAAP EPS of $1.85 to $2.05.
ITG reported second-quarter 2026 results, with revenue up 38% year over year to $404.6 million and Adjusted EBITDA up 21% to $52.2 million, but net income fell to $1.8 million from $11.6 million a year earlier. The company also issued its first full-year 2026 outlook, calling for revenue of $1,556 million and Adjusted EBITDA of $202 million, and said it completed its initial public offering in July with net proceeds mainly used to repay debt.
Revenue rose 38% year over year to $404.6 million; net income was $1.8 million versus $11.6 million in Q2 2025.
Adjusted EBITDA margin was 12.9%, down from 14.8% a year earlier, which management attributed to startup and public-company readiness costs.
FY 2026 outlook: revenue of $1,556 million (+35%) and Adjusted EBITDA of $202 million (+36%).
NTM backlog was $1,517 million as of June 30, 2026, compared with $1,259 million a year earlier.
Comscore reported second-quarter 2026 revenue of $79.2 million, down 11.3% from a year earlier, and a net loss of $14.8 million, up from $9.5 million. The company said it sold its Movies business for $70.0 million in cash and used proceeds to repay $40.1 million of senior secured debt, and it set full-year 2026 revenue guidance of $315 million to $325 million.
Q2 2026 revenue $79.2 million vs. $89.4 million in Q2 2025; Movies business contributed $6.2 million vs. $9.6 million
Net loss $14.8 million vs. $9.5 million; adjusted EBITDA $1.3 million vs. $8.9 million
Movies business sold for $70.0 million in cash, closed May 27, 2026; $40.1 million senior secured facility repaid in full
Full-year 2026 revenue outlook of $315 million to $325 million; company expects $20 million to $25 million in annual run-rate cost savings
Omeros reported second-quarter 2026 net product revenue of $28.5 million for YARTEMLEA, up from $9.9 million in the first quarter, and an operating gain of $0.1 million after a $17.4 million operating loss in the first quarter. GAAP net income fell to $13.2 million, or $0.18 per share, from $56.1 million in the first quarter, which included a larger $73.1 million non-cash gain. The company also completed July repurchases that cut its 2029 Notes principal to about $40.3 million and reduced potential conversion shares.
Net revenue of $28.5 million in Q2 2026 versus $9.9 million in Q1 2026; gross revenue was $32.2 million
Net income of $13.2 million ($0.18 per share) versus $56.1 million in Q1, with non-cash gains of $11.5 million in Q2 and $73.1 million in Q1
Non-GAAP adjusted net income of $1.8 million ($0.02 per share) in Q2 versus an adjusted net loss of $17.1 million in Q1
Cash and short-term investments of $132.0 million at June 30, 2026; 2029 Notes repurchases totaled $60.2 million in July 2026
Spero Therapeutics reported a second-quarter 2026 net loss of $9.6 million, or $0.16 per share, compared with a net loss of $1.7 million, or $0.03 per share, a year earlier. The company recognized no revenue in the quarter, versus $14.2 million in the second quarter of 2025, and said it expects cash plus the July 2026 royalty financing to fund operations into the second half of 2029.
Q2 2026 total revenue was zero, compared with $14.2 million in Q2 2025, as deferred and grant revenue had been fully recognized in prior periods.
Q2 2026 research and development expense was $3.4 million, down from $10.7 million; general and administrative expense rose to $6.5 million from $5.9 million.
Cash and cash equivalents were $50.8 million at June 30, 2026, before the $105 million royalty financing closed in July 2026.
Other events disclosed include the July 2026 exclusive license for SP001 from Innovent Biologics and the appointment of Debra Jeske Zack as Chief Medical Officer.
Cerebras reported second-quarter 2026 GAAP total revenue of $180.1 million, up 74% from a year earlier, and core revenue of $209.9 million, up 103%. The company posted a GAAP net loss of $450.5 million, compared with net income of $309.5 million a year earlier, which included a $363.3 million forward contract benefit. It raised its full-year 2026 core revenue outlook to $880 million to $890 million.
GAAP total revenue was $180.1 million, up 74% year over year; core total revenue was $209.9 million, up 103%.
GAAP net loss was $450.5 million, or $2.98 per share, versus net income of $309.5 million, or $1.91 diluted per share, in Q2 2025.
Full-year 2026 core revenue outlook raised to $880 million to $890 million; Q3 2026 core revenue expected at $214 million to $216 million.
Remaining performance obligations were $25.4 billion as of June 30, 2026.
Sera Prognostics reported second-quarter 2026 results on August 12, 2026, in a press release furnished as Exhibit 99.1. Revenue rose to $30,000 from $17,000, but operating expenses increased to $10.0 million and the net loss widened to $9.1 million from $8.0 million. The company said it ended the quarter with about $80.3 million in cash, cash equivalents and available-for-sale securities.
Q2 2026 revenue was $30,000, up from $17,000 in Q2 2025.
Net loss was $9.1 million, or $0.18 per share, versus $8.0 million, or $0.16 per share, a year earlier.
Total operating expenses were $10.0 million, compared with $9.3 million in the prior-year quarter.
Cash, cash equivalents and available-for-sale securities were about $80.3 million, which the company says will fund operations through 2029.
Talphera reported no revenue for the second quarter of 2026 and a net loss of $4.3 million, or $0.06 per share, versus a net loss of $3.5 million, or $0.10 per share, a year earlier. The dollar loss grew, but the per-share loss narrowed as weighted shares rose to 75.5 million from 34.5 million. The company said NEPHRO CRRT study enrollment reached 75%, with completion expected this year.
Net loss of $4.3 million, or $0.06 per share, for Q2 2026, compared with $3.5 million, or $0.10 per share, for Q2 2025
Combined R&D and SG&A expenses of $3.9 million, up from $3.7 million, mainly due to higher Niyad development expenses
Cash, cash equivalents and investments of $17.1 million at June 30, 2026, down from $20.4 million at December 31, 2025
NEPHRO CRRT study 75% enrolled; company regained Nasdaq compliance with the $1 bid price rule
Jack in the Box reported third quarter fiscal 2026 results with total revenues down 1.8% to $257.7 million and same-store sales down 1.1%. Diluted EPS from continuing operations fell to $1.08 from $1.19 a year earlier, while Adjusted EBITDA rose to $61.2 million from $57.1 million. The company also updated its fiscal 2026 guidance, including Adjusted EBITDA of $225 million to $230 million.
Total revenues were $257.7 million, down from $262.4 million; same-store sales declined 1.1%.
Diluted EPS from continuing operations was $1.08 versus $1.19; Operating EPS was $0.96 versus $1.04.
Adjusted EBITDA was $61.2 million versus $57.1 million; the company did not repurchase shares in the quarter.
Updated fiscal 2026 guidance includes Adjusted EBITDA of $225 million to $230 million and about 2,100 restaurants at year end.
Inovio reported a second-quarter 2026 net loss of $6.0 million, or $0.07 per share, down from $23.5 million, or $0.61 per share, a year earlier. The company said the decline was driven mainly by a $13.9 million non-cash gain on warrant liabilities, while operating expenses fell to $18.6 million from $23.1 million. Cash and short-term investments were $36.7 million at June 30, 2026, down from $58.5 million at December 31, 2025, before about $18.3 million in July offering proceeds.
Net loss of $6.0 million, or $0.07 per share, versus $23.5 million, or $0.61 per share, in Q2 2025
Non-cash warrant liability gain of $13.9 million; total operating expenses fell to $18.6 million from $23.1 million
Cash, cash equivalents and short-term investments of $36.7 million at June 30, 2026, excluding about $18.3 million in July offering proceeds
Cash expected to fund operations into late first quarter 2027, through a potential INO-3107 launch if approved; FDA PDUFA target date is October 30, 2026
OptimizeRx reported second-quarter 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, and a GAAP net loss of $0.7 million, compared with net income of $1.5 million in the prior-year quarter. The company reaffirmed its fiscal 2026 guidance of $95 million to $100 million in revenue and $21 million to $25 million in adjusted EBITDA, and said it will also transition its finance leadership, with Andy D'Silva becoming CFO and Heather Favazza Chief Accounting Officer on January 1, 2027.
Q2 2026 revenue was $20.5 million, down from $29.2 million in Q2 2025; adjusted EBITDA was $4.9 million, down from $5.8 million
GAAP net loss was $(0.7) million, or $(0.04) per share, versus net income of $1.5 million, or $0.08 per share, a year earlier
Fiscal 2026 guidance reiterated: revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million
Edward Stelmakh steps down as Chief Financial & Strategy Officer effective December 31, 2026, and will serve as an advisor through December 31, 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.